



Antibiotice **at**

**70 years of trust, performance
and lasting partnerships**

Key results recorded in H1 2026

342.3
mil lei

Total revenue of
342.3 million lei.

13.7%

Gross profit cumulated with the
value of the claw-back tax
generated a 13.7% business
return.

+5%

The sales of *finished products*
and *active substances* were 5%
higher compared with the same
period of 2025.

Ranked 4th

Consolidated in terms of boxes
consumed in the Romanian
prescription and non-prescription
generics market, with a 5.5%
market share.

Ranked 1st

Market value leader in the hospital
segment for prescription and non-
prescription generics, with a 12.3%
market share.

2.0919
lei


Average value of shares:
2.0919 lei/share.

930.7
mil lei

The net book value of the assets
amounted to 930.7 million lei, in
line with 2025.

Antibiotice S.A. - a performance-oriented company

- » ATB symbol
- » Listing date: April 16, 1997
- » Market capitalization: 1.45 billion lei*
- » Number of shares: 671,338,040
- » Nominal share value: 0.10 lei/share
- » Share capital: 67 million lei
- » Minimum price: 1.7520 lei/share
- » Maximum price: 2.5500 lei/share




Antibiotice - a company worth working for

Highly-educated specialists (54% - 723)

**Employees with secondary education
(47% - 631)**


1,354 EMPLOYEES

- Highly-educated specialists Top specializations



- chemical engineers - 20.24%
- economists - 21.85%
- chemists, physicists, biologists - 17.83%
- engineers of other specializations - 14.34%
- pharmacists, doctors, medical bioengineers - 16.49%
- other professions - 9.25%

Employees with secondary education Top professions



- pharmaceutical site operator - 41.24%
- active substance site operator - 17.33%
- production equipment operations and maintenance operator, machine operator, automation operator, mechanic, technician - 18.27%
- quality control laboratory technician - 13.18%
- logistics operator - 5.65%
- electrician - 4.33%

→ 97.71% - employee retention rate as of 30.06.2026

→ 23 hours – average number of training hours /employee as of 30.06.2026

Antibiotice - a knowledge- and performance-driven company

ACADEMIA a+ , a knowledge management platform (staff recruitment and business skills development)

TECHNICAL COLLEGE a+



BUSINESS SCHOOL a+



PRE-UNIVERSITY& UNIVERSITY ENVIRONMENT

- ❑ Internships for **178 pupils** from the technical and dual education and for **185 students and resident physicians and pharmacists**;
- ❑ Educational visits within the “**Different Week**” program for **435 pupils and 80 students**;
- ❑ Partner of the **Center of Excellence** for students of the **Faculty of Economics and Business Administration**;
- ❑ The “**Education in Action**” project: **Improving the Accessibility and Relevance of Vocational and Technical Education through Internships within Antibiotice S.A.**”. In the reporting period, **139 pupils** were part of the target group;
- ❑ the “**AntibioticeSkills project: Improving students’ skills and their adaptation to the labor market.**” In the reporting period, **122 students** were included in the target group.

BUSINESS SKILLS DEVELOPMENT

- ❑ In the H1 2026, over **32,505 training hours** were conducted, with over **1,400 employees attendances**;
- ❑ Since its launch, the **e-learning platform** has reached a total of **650 users**, with approximately **8,950 hours** completed by the participants, with **1,300 certifications** granted in the fields such as marketing and communication, personal development, conformity, occupational health and security, team management, MS Office, customer service;
- ❑ **Bookster**, a program launched in 2020 that gives employees the opportunity to borrow books: **335 active users** and over **21,259 free book loans**.

Antibiotice in the service of life for a lifetime

12 therapeutic classes – 199 products
> 500 marketing authorizations in over 50 countries
38 critical products
56 essential products

Oral Solid Products Division

99 products for human use:

- **prescription-only medicinal products** within the following therapeutic classes:
 - anti-infectives for systemic use (penicillins, cephalosporins, fluoroquinolones, macrolides, tetracyclines, antituberculosis, antivirals);
 - cardiovascular system;
 - digestive tract and metabolism;
 - central nervous system;
- **non-prescription products** complementary to prescription medication

Topical Products Division

56 products for human use:

- **products intended for the treatment of:**
 - dermatological conditions;
 - musculoskeletal conditions;
 - genitourinary conditions;
 - hemorrhoidal conditions;
 - ophthalmic conditions.

Sterile Products Division

40 products for human use:

- prescription anti-infectives for systemic use (from the β -lactam penicillins, cephalosporins, carbapenems, polymyxin, tetracycline, glycopeptides);
- non-prescription medicines (OTCs).

Active Substances Division

The range of active substances **Nystatin** is obtained through the biosynthesis, by cultivating the microorganism **Streptomyces noursei** on nutrient media, followed by the processes of isolation and purification of the active substance.

Antibiotice - a company operating at international standards



EU GMP

8 manufacturing flows



US FDA

Sterile injectable powders and Nystatin, active substance



COS (Certificate of Suitability) issued by EDQM

Standard și micronized Nystatin



ISO TUV RHEINLAND certification for integrated management

Quality, environment, occupational health and safety ISO 9001, ISO 14001, ISO 45001



EcoVadis – Global Sustainability Assessment Platform

Our company obtained the Silver medal which places it in the "Advanced" category and in the top 15% of companies analyzed globally in the pharmaceutical industry.

Antibiotice - in the pharmaceutical market in Romania

In the HI 2026, on the domestic market, Antibiotice S.A.:

ranked 1st, as number of boxes in the total anti-infectives market (21.7% out of a total of 72 companies).


maintained its **4th rank** (out of a total of 368 companies) in terms of consumption (no. of boxes) in the generic Rx and non-Rx medicines segment (5.5% market share).

leader in terms of quantity (IU) in the total market for the following pharmaceutical dosage forms: ointments (19.9% out of a total of 132 companies), suppositories and pessaries (34.1% out of a total of 54 companies) and powders for injection (59.5% out of a total of 57 companies).

leader in terms of value in the generic Rx and non-Rx medicines segment traded in hospitals, with a 12.3% market share, in a market where 230 companies operate.

Antibiotice - an international brand

Present in over 50
countries worldwide



Commercial representations (marketing and sales)


North America (USA, Canada)
South America (Brazil, Mexico, Columbia)
Europe (UK, Germany, Italy, the Nordic Countries)
India
China
Australia

**World leader in the
production of active
substance Nystatin, an
antifungal antibiotic**

Business representatives:


Republic of Moldova
Serbia
Vietnam
Saudi Arabia

Antibiotice - an internationally recognized Romanian brand



Indicators	30 June 2026	30 June 2025	30 June 2026 / 30 June 2025
A. Total revenues, of which:	342.259.104	380.160.338	-9,97%
1. Operating revenues	330.186.451	370.200.532	-10,81%
1.1 Revenue from contracts with customers (revenue), of which:	299.128.061	333.740.008	-10,37%
revenue from sales of products manufactured at own sites	249.120.736	255.974.948	-2,68%
revenue from sales of products manufactured at partner sites	49.358.883	76.503.868	-35,48%
revenue from services rendered	648.442	1.261.192	-48,59%
1.2 Other operating income	4.293.252	395.376	985,87%
1.3 Grant income	250.077	208.244	20,09%
1.4 Changes in inventories of finished products and work in progress	18.939.274	30.411.726	-37,72%
1.5 Income from capitalised projects	7.575.786	5.445.179	39,13%
2. Financial income	12.072.653	9.959.805	21,21%
Foreign-exchange gains	12.072.345	9.958.599	21,23%
Bank interest income	308	1.206	-74,45%
B. Total expenses, of which:	321.911.149	311.865.305	3,22%
1. Operating expenses:	299.389.450	295.057.797	1,47%
Raw materials and materials expenses	90.125.843	88.825.400	1,46%
Expenses for products manufactured at partner sites	35.345.893	44.036.764	-19,74%
Electricity expenses	4.912.920	5.132.186	-4,27%
Natural gas expenses	5.207.315	6.048.146	-13,90%
Potable water and sewerage expenses	1.564.294	1.337.918	16,92%
Employee benefit expenses	82.025.568	79.895.912	2,67%
Other operating expenses (*)	51.524.178	43.809.494	17,61%
Depreciation, amortisation and impairment adjustments for non-current assets, net	28.683.440	25.971.977	10,44%
2. Financial expenses	22.521.699	16.807.508,1	34,00%
Foreign-exchange losses	19.722.222	14.607.803	35,01%
Bank interest expenses	2.799.477	2.199.705	27,27%
Operating profit	30.797.001	75.142.735	-59,02%
Financial result	-10.449.046	-6.847.703	52,59%
Gross profit	20.347.955	68.295.032	-70,21%
Income tax expense	4.861.265	9.171.237	-46,99%
Net profit	15.486.690	59.123.795	-73,81%

H1 2026 Investment Plan Implementation



Antibiotice

Știință și suflet



www.antibiotice.ro

